Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... The vast majority of Americans believe it’s ... their level of physical activity, the healthfulness of their ... taking that control. Those are among the findings ... Food & Health Survey. , According to the Survey, ... “a great deal of control” or “complete control” over ...
(Date:5/23/2013)... 2013 Jeanne Ettelson, president of ... popular and only free OCD support group in Chicago. ... for OCD sufferers, the group is lead by psychologists ... This allows group participants to learn accurate information ... Prevention. , “Participants in Beyond OCD’s support group ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Schools should ensure ... physical activity each day to support their health ... new report. Although previous studies show ... promotes health and development, it,s estimated that only ... meeting this recommendation, according to the report from ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- Heavy consumption of ... or crack cocaine, a new study contends. "You ... mouth, it is startling to see the intensity and ... Dr. Mohamed Bassiouny, a professor of restorative dentistry at ... Methamphetamine, crack cocaine and soda -- sweetened or not ...
(Date:5/23/2013)... that an immune regulatory molecule called IL-21 is needed ... , The results are published in the Journal ... could be important in the development of antiviral vaccines," ... first author of the paper. The senior author is ... and a Georgia Research Alliance Eminent Scholar. , The ...
Breaking Medicine News(10 mins):Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2
... HealthDay Reporter , WEDNESDAY, July 6 (HealthDay News) ... pain, a silver bullet to alleviate the condition has yet ... studies comparing spinal manipulative therapy (SMT) to other treatments such ... found that SMT appears to be no better or worse ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, July ... health and well-being of America,s children brings forth some good ... drinking, preterm birth rates are dropping and deaths from injury ... several negative trends. More eighth-graders are using drugs, more children ...
... University of Southampton have developed smart nanomaterials, which can ... team of researchers, led by Physics lecturer Dr Antonios ... can activate or inhibit genes that are involved in ... of oxygen and nutrients to most types of cancer. ...
... Hearing has a key role in the acquisition of ... with a hearing impairment. Early diagnosis and treatment can ... issue of Deutsches rzteblatt International , Martin Ptok ... reliably detects hearing defects, the benefits of early diagnosis, ...
... 7 (HealthDay News) -- Individual concussion baselines need to be ... season for them to be accurately diagnosed and treated if ... The investigators also noted that the sex of the players ... The study included 1,134 high school athletes in the Phoenix ...
... Creating a baseline for each ... concussion assessment, according to researchers presenting their study at ... in San Diego. Differences in how females and males ... investigated. "Our research analyzed whether the new ...
Cached Medicine News:Health News:Study Questions Chiropractic's Impact on Back Pain 2Health News:Study Questions Chiropractic's Impact on Back Pain 3Health News:Fewer U.S. Teens Having Babies, Binge Drinking: Report 2Health News:Fewer U.S. Teens Having Babies, Binge Drinking: Report 3Health News:Teen Athletes Should Get Concussion Test Score Before Play 2Health News:Concussion baseline important for accurate future assessment in at-risk youth athletes 2
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... CeloNova BioSciences, Inc.,("CeloNova"), leading and accelerating ... innovative medical devices, has released data,from THE ... study of uterine fibroid,embolization using the Company,s ... the 20th Annual International Symposium on,Endovascular Therapy., ...
... Disease Indication for HUMIRA Provides Patients with Visible, ... Chronic Autoimmune Disease, ABBOTT PARK, Ill., Jan. ... it has received U.S. Food and Drug Administration ... for adult patients,with moderate to severe chronic plaque ...
Cached Medicine Technology:CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 3Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 4Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 5Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 6Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 7
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: